TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04908163

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet-based nutritional education intervention
Description: The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet-based culinary intervention
Description: The culinary intervention will be developed integrating eight culinary and nutritional workshops that will be given every week, twice per week, during one-month intervention. The duration of each culinary and nutritional workshop will be 1 hour, thus, the program will provide a total of hours of nutritional education and a total of 8 hours of nutritional and cooking training. The courses will take place in a well-equipped kitchen from the Basque Culinary Center and participants will be connected online in order to be able to cook and practice at the same time. All cooking classes will begin with a theoretical introductory part that aim to explain the main take-home messages from the workshop. Subsequently, every class will be characterized by a hands-on part that will include the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients.
Study: NCT05759221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with airway biopsy
Description: Forceps biopsy of peripheral airways under direct endoscopic visualisation.
Study: NCT05475223

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: End Tidal Carbon Monoxide Value
Description: A noninvasive ETCO value will be obtained by inserting a soft silicon cannula placed in the baby's nostril for a few minutes to measure exhaled end tidal carbon monoxide; a value corrected for ambient ETCO value will be recorded.
Study: NCT05357287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PREVENA incision management system
Description: We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
Study: NCT05659758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head up positioning during preoxygenation
Description: patients will be preoxygenated in head up position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head up positioning during preoxygenation
Description: patients will be preoxygenated in head up position

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Head up positioning during preoxygenation
Description: patients will be preoxygenated in head up position
Study: NCT05612776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: HIIT training will consist of performing high intensity intervals along with passive rests. The intensity of the exercise will be progressively increased and the rest time will be decreased. All participants will perform the same training according to the maximum heart rate reached in the Bruce test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV
Description: The intervention group will perform HRV-based training, measuring HRV every day before training in order to obtain HRV normality ranges for each participant. If the HRV value is within the normal range, the participant will perform a high intensity training but if the HRV value is below the normal range, the participant will perform a continuous training at low intensity as active rest.
Study: NCT05128929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hymecromone (H01)
Description: 800 mg oral H01 two times a day (total dose: 1600 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet placebo (inactive ingredients) two times a day.
Study: NCT05573386

Intervention type: DRUG
Intervention: Filgrastim
Description: human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe

Intervention type: DRUG
Intervention: Filgrastim
Description: human granulocyte colony-stimulating factor (G-CSF) protein obtained from the bacterial fermentation of a strain of E. coli. transformed with a genetically engineered plasmid containing the human G-CSF gene; administered via syringe
Study: NCT05573386

Intervention type: DRUG
Intervention: Pegfilgrastim
Description: long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe

Intervention type: DRUG
Intervention: Pegfilgrastim
Description: long-acting covalent conjugate of recombinant methionyl human filgrastim and monomethoxypolyethylene glycol (PEG); administered via syringe
Study: NCT06267430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kleuter Extra training program
Description: The intervention was described in the included arm/group explanation.
Study: NCT06726889

Intervention type: BEHAVIORAL
Intervention: Decision Support System (DSS)
Description: DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link
Study: NCT06570395

Intervention type: PROCEDURE
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic Manipulative Therapy (OMT) is a hands-on approach to treating conditions that affect all areas of the body. Physicians trained in OMT (Doctors of Osteopathic Medicine or DO) use OMT to correct structural imbalances in the body, relieve pain, and improve circulation. It is not only used as a treatment modality, but also to diagnose and prevent disease and improve overall functioning. There are over 40 OMT techniques that all involve gentle manipulation of the muscles, soft tissues, and joints in several ways to optimize alignment, improve blood flow, restore balance, and improve range of motion (Osteopathic Manipulative Therapy \& OMT. Cleveland Clinic).
Study: NCT05940259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P3
Description: 68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Study: NCT06038318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRISM Program Video Coach
Description: A 6-session, skills-based, manualized resilience education program delivered via video coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by a HIPAA compliant videoconferencing platform, Zoom, approximately every 1-2 weeks based on participant preference. For participants who do not have smartphones, temporary equipment will be provided.
Study: NCT05832177

Intervention type: BEHAVIORAL
Intervention: Cancer CientoUno (101) program
Description: The Spanish version of Cancer 101 consists of several modules that address cancer control and prevention, risk factors, early detection and screening guidelines, cancer diagnosis and stages, cancer treatment, cancer and genetics, cancer and chronic disease, patient and caregiver support, HPV, biobanking, and clinical trials. All modules contain a written summary with learning objectives, a PowerPoint presentation, pre- and post-module evaluations with an answer sheet, a glossary, references, and supplemental resources. This program will occur on an ongoing basis.

Intervention type: BEHAVIORAL
Intervention: Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)
Description: This is a biennial cancer symposium focused on cancer topics important to Hispanic/Latinos. This day-long event includes a plenary session and concurrent sessions where healthcare professionals present educational information about cancer, cancer prevention, early detection methods, and other related topics.

Intervention type: BEHAVIORAL
Intervention: ¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)
Description: This is an educational and community outreach effort comprised of local charlas (talks) led by Hispanic/Latino healthcare professionals (e.g., the partnership Community Health Educator \[CHE\], topic experts) who provide education and answer questions about specific cancer topics. The charlas may be conducted in multiple modalities (in person, virtual, hybrid) and may be conducted in English and/or Spanish. At least three events will be held each year in the partnership locations.

Intervention type: BEHAVIORAL
Intervention: Community/Researcher Forum: El Puente (Translation in English: The Bridge).
Description: The main goal of the El Puente annual event is to generate dialogue between community members and researchers about cancer treatment and cancer-focused research topics. During El Puente's presentations, researchers present their projects and data results to community members, allowing community members to react to the research, make suggestions, and express concerns.

Intervention type: BEHAVIORAL
Intervention: Lunch and Learn Updated Recommendations Series.
Description: This is a virtual podcast that will discuss cancer-related recommendations and guidelines from the United States Preventive Services Task Force (USPSTF). The podcasts are pre-recorded, 30 minute long, and will be in English and/or Spanish. This podcast will be hosted by the Outreach Core (OC) CHE, and feature experts who will explain the updated recommendations and active steps that community members and providers can take to facilitate adherence. This activity will begin according to the project timeline
Study: NCT05918770

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: systematic screening and early treatment
Description: in case of positive screening, the online app will alert and the patient will be referred to the corresponding area for diagnosis and early treatment (Rehabilitation, Psycho-oncology, Sexual health and Nutrition
Study: NCT06088277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TM HIV
Description: Participants will receive 5 intervention text messages (TM) about HIV risk and testing per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TM HL
Description: Participants will receive 5 intervention text messages (TM) about promoting healthy living (HL) per week for the first 3 months and 3 messages per week for the last 3 months of the intervention.
Study: NCT06652490

Intervention type: PROCEDURE
Intervention: Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.
Description: In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial.

Intervention type: PROCEDURE
Intervention: Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.
Description: In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial.
Study: NCT06038318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRISM Program Text Coach
Description: A 6-session, skills-based, manualized, resilience education program delivered via text coaching by trained English or Spanish speaking PRISM coaches. Participants will have complete access to the PRISM Program mobile app. Sessions will be delivered by HIPAA compliant SMS text-messaging service, Zoom, approximately every other week. For participants who do not have smartphones, temporary equipment will be provided.
Study: NCT04380740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the extended dosing of abatacept, those randomized to receive 4 doses will receive a placebo consisting of an equal volume of normal saline solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept
Description: Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Investigational prophylaxis with extended-dosing abatacept, a calcineurin inhibitor and methotrexate.
Study: NCT05832177

Intervention type: BEHAVIORAL
Intervention: Community Engagement (CE) Training Program for U54 Partnership Investigators
Description: This is a series of 2 1/2-day CE workshops designed and delivered up to 20 partnership researchers (including faculty and junior investigators) delivered across four sessions per year (6 to 10 researchers per year). Each session includes two hours of lectures (didactic material) and one hour of practice activities (practical application of the theoretical content). Session topics will include CE: concepts and principles, theoretical roots, levels, and ethics. The OC team will provide educational materials and additional references in each session.

Intervention type: BEHAVIORAL
Intervention: Community Advisory Panels (CAP)
Description: These CAPs work closely with the (CHE) to oversee the identification, development, and coordination of the outreach activities; provide advice on the development and implementation of community needs and assessments; provide guidance for recruitment and retention of research participants; and assist in the recruitment for educational events and research and vetting community educational materials and the content of protocols for research projects.

Intervention type: BEHAVIORAL
Intervention: Research Corner
Description: The goal is to provide bidirectional communication between the community and researchers to increase CE strategies into cancer disparities research through periodic meetings between community members and researchers to discuss CE strategies, research recruitment strategies, dissemination strategies, among others.
Study: NCT06038318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPRISM Program App
Description: 6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mPRISM Program App
Description: 6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mPRISM Program App
Description: 6 static modules to practice skills-based, manualized, resilience education program delivered via PRISM Program mobile app. For participants who do not have smartphones, temporary equipment will be provided.
Study: NCT05832177

Intervention type: BEHAVIORAL
Intervention: Community-based Training Program (CBTP) for Community Leaders and Stakeholders.
Description: The CBTP provides the opportunity to acquire knowledge to impart cancer prevention education (Cancer 101) and skills necessary to disseminate educational information (hands-on experiences through OC educational activities). This training will be provided in-person and remotely to increase participation. This activity will begin according to the project timeline.
Study: NCT04937738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT06481501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONE Mindfulness-Oriented Recovery Enhancement
Description: One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
Study: NCT05832177

Intervention type: BEHAVIORAL
Intervention: Integrate Cancer 101 into the Stakeholders Programs
Description: This program will offer stakeholders a no-cost workshop of three credit hours to increase cancer prevention education among Hispanic/Latinos. CMEs will be provided virtually to increase participation. This activity will begin according to the project timeline.

Intervention type: BEHAVIORAL
Intervention: Community Engagement (CE) Training Program for Lay Community Members
Description: A series of two-day CE workshops designed and delivered to 30 lay community members over a four-year period (6 to 10 participants per year). The proposed CE workshops includes: 1) CE principles, 2) cancer prevention education principles, and 3) community-based promotion strategies for cancer prevention. This activity will begin according to the project timeline.
Study: NCT06640634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)
Description: Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days.
Study: NCT05567406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study: NCT06578949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Ravulizumab will be administered by intravenous (IV) infusion.
Study: NCT06286644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iso-alpha-Acids
Description: Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xanthohumol + Iso-alpha-Acids
Description: Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
Study: NCT05325424

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic splenectomy
Description: The laparoscopic splenectomy was performed by the same surgical team.
Study: NCT04937738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m²d1 i.v. every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m² two times per day (BID), d1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m² d1 i.v. every 3 weeks
Study: NCT04937998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous PRP injection
Description: Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HA injection
Description: Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
Study: NCT05104502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Fasting
Description: The study will consist of two days of eating a controlled habitual diet and one 36-hour period of water-only fasting with glucose monitoring as a measure of compliance. Water intake will be limited to 2 liters/day to prevent electrolyte abnormalities. Subjects will undergo 4 separate blood-draws consisting of an overnight fasted sample (Baseline), a 2-hour postprandial sample (Fed), a 36-hour fasted sample (Fasted), and final 2-hour postprandial sample after the fasting period (Refed).
Study: NCT05741502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: We will assess inflammatory/immune marker labs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotics,Other (non-Clozapine)
Description: We will assess monitor inflammatory/immune marker lab